RSA测试的TKA假体平均10年翻修率低于非RSA测试设计
本研究通过国家膝关节置换登记系统比较经RSA测试与非RSA测试TKA设计的5年和10年全因翻修率,发现RSA测试组翻修率略低,5年差异0.6%,10年差异0.9%,提示RSA测试可能有助于降低翻修负担。
要点
- RSA测试TKA假体5年全因翻修率平均低0.6%,10年低0.9%。
- 10年翻修率:非RSA测试5.5%,RSA测试4.4%。
- 1%的风险差异可能转化为高达10年约20%的翻修负担下降。
核心结论
- RSA测试的TKA设计在5年和10年随访时平均全因翻修率略低于非RSA测试设计,差异约1%。
研究设计与样本
- 研究纳入7个国家膝关节置换登记系统,共339个TKA设计,其中236个为RSA测试,103个为非RSA测试。
- 5年随访时分析191个非RSA测试和92个RSA测试设计;10年随访时分析154个非RSA测试和74个RSA测试设计。
主要发现
- 5年全因翻修率:非RSA测试3.6%(95%CI 3.4-3.8),RSA测试2.9%(95%CI 2.7-3.0),平均差异0.6%(95%CI 0.4-0.8;p<0.001) favoring RSA测试假体。
- 10年全因翻修率:非RSA测试5.5%(95%CI 5.2-5.9),RSA测试4.4%(95%CI 4.1-4.7),平均差异0.9%(95%CI 0.4-1.3;p<0.001) favoring RSA测试假体。
关键数值与推荐
- RSA测试假体5年翻修率平均低0.6%(95%CI 0.4-0.8)。
- RSA测试假体10年翻修率平均低0.9%(95%CI 0.4-1.3)。
临床怎么用
- 在引入新TKA设计前,可考虑采用RSA测试以预测长期翻修风险。
- 临床选择TKA假体时,可参考RSA测试证据作为降低翻修率的潜在指标。
局限性
- 本研究为观察性研究,存在固有局限性。
- 部分登记系统因缺乏10年数据或未报告翻修率而被排除,可能影响结果代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The number of revisions after TKA is expected to rise because of aging populations in many countries and because patients are undergoing TKA at younger ages. Aseptic loosening is a major reason for late revision, which can be predicted by radiostereometric analysis (RSA) of small groups of patients at 2 years of follow-up. RSA is therefore an ideal tool to assess new TKA designs before they are introduced to the market, although not every TKA design has been studied with RSA. If RSA-tested TKA designs have lower 10-year revision rates in national registries than non-RSA-tested TKA designs, RSA testing of all new designs could be advocated. QUESTIONS/PURPOSES: In this study, we asked: Is there a difference in the all-cause revision rate between non-RSA-tested and RSA-tested TKA designs registered in national knee arthroplasty registries at 5 and 10 years of follow-up? METHODS: Knee arthroplasty registries were identified through the European Federation of National Associations of Orthopaedics and Traumatology webpage and through a manual internet search. Inclusion criteria were a minimum follow-up duration of 10 years and available revision or survival data per TKA design. Twenty-six registries were identified; seven were included comprising 339 TKA designs, of which 236 designs were classified as RSA-tested and 103 as non-RSA-tested. Six registries were excluded because no report was published. One registry was excluded because no fixation method was mentioned (79 TKA designs). Another registry was excluded because there was no 10-year data available (22 non-RSA-tested designs; 10 RSA-tested designs). Eleven registries were excluded because they did not provide revision rates per design and had not reached 10 years follow-up. The revision rates with their standard errors were extracted per design. We used the data from a recent meta-analysis to identify whether a TKA design was previously tested with RSA. This meta-analysis found 53 RSA studies comprising 70 different TKA designs. The prosthesis model, fixation method and insert type were extracted from these RSA-studies. The design characteristics of the TKA reported in the knee arthroplasty registries were also extracted, and if possible, matched to the TKA designs reported in the RSA-studies. At 5 years of follow-up, 191 TKA designs were identified as non-RSA-tested and 92 were identified as RSA-tested. At 10 years of follow-up, 154 TKA designs and 74 TKA designs were classified as non-RSA-tested and RSA-tested, respectively. A random-effects model using the Metafor Package in R statistics was used to estimate the pooled revision rate at 5 and 10 years of follow-up for both groups. The difference in revision rates between groups at 5 and 10 years of follow-up was estimated by including RSA as a factor in the random-effects model. RESULTS: Mean all-cause revision rates at 5 years for non-RSA-tested and RSA-tested implants were 3.6% (95% CI 3.4 to 3.8) and 2.9% (95% CI 2.7 to 3.0), with a mean difference of 0.6% favoring RSA-tested implants (95% CI 0.4 to 0.8; p < 0.001). Mean all-cause revision rates at 10 years for non-RSA-tested and RSA-tested implants were 5.5% (95% CI 5.2 to 5.9) and 4.4% (95% CI 4.1 to 4.7), with a mean difference of 0.9% favoring RSA-tested implants (95% CI 0.4 to 1.3; p < 0.001). CONCLUSIONS: Although there are exceptions, across registries, TKA designs that have been tested in an RSA setting have a slightly lower (about 1%) mean all-cause revision rate at 5-year and 10-year follow-up than those tested in a non-RSA setting. Acknowledging the inherent limitations of this observational study, a risk difference of 1% could potentially translate into an approximate 20% decrease in revision burden up to 10 years, which may have a profound impact on patient morbidity and health-related costs. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Hasan S, Marang-van de Mheen PJ, Kaptein BL, et al. RSA-tested TKA Implants on Average Have Lower Mean 10-year Revision Rates Than Non-RSA-tested Designs. Clin Orthop Relat Res. 2020. PMID: 32187101. doi:10.1097/CORR.0000000000001209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。